82 related articles for article (PubMed ID: 19765373)
1. [Efficient combination of clavulanate and beta-lactam antibiotics against extensively drug-resistant M. tuberculosis].
Hugonnet JE
Med Sci (Paris); 2009; 25(8-9):661-3. PubMed ID: 19765373
[No Abstract] [Full Text] [Related]
2. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
Dinçer I; Ergin A; Kocagöz T
Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
[TBL] [Abstract][Full Text] [Related]
3. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.
Egesborg P; Carlettini H; Volpato JP; Doucet N
Protein Sci; 2015 Apr; 24(4):534-44. PubMed ID: 25492589
[TBL] [Abstract][Full Text] [Related]
5. Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.
Viswanathan G; Yadav S; Raghunand TR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438925
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis.
Wivagg CN; Bhattacharyya RP; Hung DT
J Antibiot (Tokyo); 2014 Sep; 67(9):645-54. PubMed ID: 25052484
[TBL] [Abstract][Full Text] [Related]
7. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate.
Tremblay LW; Hugonnet JE; Blanchard JS
Biochemistry; 2008 May; 47(19):5312-6. PubMed ID: 18422342
[TBL] [Abstract][Full Text] [Related]
8. Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif.
Soroka D; Li de la Sierra-Gallay I; Dubée V; Triboulet S; van Tilbeurgh H; Compain F; Ballell L; Barros D; Mainardi JL; Hugonnet JE; Arthur M
Antimicrob Agents Chemother; 2015 Sep; 59(9):5714-20. PubMed ID: 26149997
[TBL] [Abstract][Full Text] [Related]
9. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
Holzgrabe U
ChemMedChem; 2009 Jul; 4(7):1051-3. PubMed ID: 19462395
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
Solapure S; Dinesh N; Shandil R; Ramachandran V; Sharma S; Bhattacharjee D; Ganguly S; Reddy J; Ahuja V; Panduga V; Parab M; Vishwas KG; Kumar N; Balganesh M; Balasubramanian V
Antimicrob Agents Chemother; 2013 Jun; 57(6):2506-10. PubMed ID: 23507276
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis and beta-lactam antibiotics.
Gun MA; Bozdogan B; Coban AY
Future Microbiol; 2020 Jul; 15():937-944. PubMed ID: 32762449
[TBL] [Abstract][Full Text] [Related]
12. Phosphate Promotes the Recovery of Mycobacterium tuberculosis β-Lactamase from Clavulanic Acid Inhibition.
Elings W; Tassoni R; van der Schoot SA; Luu W; Kynast JP; Dai L; Blok AJ; Timmer M; Florea BI; Pannu NS; Ubbink M
Biochemistry; 2017 Nov; 56(47):6257-6267. PubMed ID: 29087696
[TBL] [Abstract][Full Text] [Related]
13. Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Segura C; Salvadó M; Collado I; Chaves J; Coira A
Antimicrob Agents Chemother; 1998 Jun; 42(6):1524-6. PubMed ID: 9624510
[TBL] [Abstract][Full Text] [Related]
14. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
Hugonnet JE; Tremblay LW; Boshoff HI; Barry CE; Blanchard JS
Science; 2009 Feb; 323(5918):1215-8. PubMed ID: 19251630
[TBL] [Abstract][Full Text] [Related]
15. Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
van Rijn SP; Srivastava S; Wessels MA; van Soolingen D; Alffenaar JC; Gumbo T
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696238
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
Li C; Nicolau DP; Lister PD; Quintiliani R; Nightingale CH
J Antimicrob Chemother; 2004 Feb; 53(2):297-304. PubMed ID: 14729755
[TBL] [Abstract][Full Text] [Related]
17. Have we realized the full potential of β-lactams for treating drug-resistant TB?
Story-Roller E; Lamichhane G
IUBMB Life; 2018 Sep; 70(9):881-888. PubMed ID: 29934998
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.
Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC
Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013
[TBL] [Abstract][Full Text] [Related]
19. A Bacteroides thetaiotamicron porin that could take part in resistance to beta-lactams.
Behra-Miellet J; Calvet L; Dubreuil L
Int J Antimicrob Agents; 2004 Aug; 24(2):135-43. PubMed ID: 15288312
[TBL] [Abstract][Full Text] [Related]
20. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate.
Hugonnet JE; Blanchard JS
Biochemistry; 2007 Oct; 46(43):11998-2004. PubMed ID: 17915954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
